SCHEMBL20577985

SCHEMBL20577985

Nc1cccc(NC(=O)O)c1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HDAC1 Q13547 8/20 0.46
HDAC3 O15379 7/20 0.46
HDAC2 Q92769 7/20 0.46
MAPK1 P28482 2/20 0.46
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
KDM4E B2RXH2 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
NCOR2 Q9Y618 4/20 0.41
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
HDAC4 P56524 3/20 0.40
HDAC7 Q8WUI4 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647589 0.83 HDAC1 (0.49) MEN1KMT2AHDAC1HDAC3HDAC2
SCHEMBL2089517 0.80 KMT2A (0.52) MEN1KMT2AMAPK1NPC1RAB9A
SCHEMBL653241 0.79 HDAC3 (0.68) MEN1KMT2AHDAC1HDAC3HDAC2
SCHEMBL3095423 0.78 MMP2 (0.52) HDAC1HDAC3HDAC2MAPK1NPC1
SCHEMBL11291980 0.78 NPC1 (0.57) HDAC1HDAC3HDAC2MAPK1NPC1
SCHEMBL17398523 0.77 RIPK1 (0.49) MEN1KMT2ARAB9ALMNA
SCHEMBL15551470 0.77 HDAC1 (0.55) MEN1KMT2AHDAC1HDAC3HDAC2
SCHEMBL3415512 0.77 KMT2A (0.49) MEN1KMT2AMAPK1NPC1RAB9A
SCHEMBL11290401 0.77 CDC25B (0.58) HDAC1HDAC3HDAC2MAPK1NPC1
SCHEMBL1847415 0.76 EPHX2 (0.58) MEN1KMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2020-11-24 US disclosed
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2019-10-03 US disclosed
EP-3412670-A1 PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2018-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof BRAF, KDR, RAF1 MEN1 1284/4885KMT2A 3193/4885HDAC1 1995/4885
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof BRAF, KDR, RAF1 MEN1 1284/4885KMT2A 3193/4885HDAC1 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.